Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 8/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5662013 | 1.00 | PSMB5 (0.37) | PSMB5DPP4DPP8DPP9DPP7 | |
| SCHEMBL10582214 | 0.88 | SLC7A5 (0.38) | PSMB5ANPEPDNPEPMMP2SLC7A5 | |
| SCHEMBL6558952 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL27601749 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL4638730 | 0.85 | DPP4 (0.46) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL9813485 | 0.83 | MMP2 (0.38) | PSMB5TERTMMP2 | |
| SCHEMBL11761746 | 0.81 | PSMB5 (0.42) | PSMB5TERTANPEPDNPEP | |
| SCHEMBL16620266 | 0.81 | DPP4 (0.39) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL9125697 | 0.81 | PSMB5 (0.41) | PSMB5 | |
| SCHEMBL9125703 | 0.81 | PSMB5 (0.41) | PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1267898-A4 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIV MARYLAND (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | UNIVERSITY OF MARYLAND, BALTIMORE | 2003-11-13 | — | — | US | disclosed |
| EP-1267898-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | University of Maryland, Baltimore (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001076531-A2 | BILE ACID CONTAINING PRODRUGS WITH ENHANCED BIOAVAILABILITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212051-A1 | Bile acid containing prodrugs with enhanced bioavailabilty | SLC10A2, SLC10A1, NR1H4 | PSMB5 4563/4885DPP4 321/4885DPP8 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.